International Clinical Psychopharmacology最新文献_第4页

The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study. 鲁拉西酮对精神分裂症5个症状域和个体项目的影响：来自3期研究的事后分析。

IF 3 3区医学

International Clinical Psychopharmacology Pub Date : 2026-05-01 Epub Date: 2025-12-11 DOI: 10.1097/YIC.0000000000000609

Itaru Miura, Kentaro Takai, Shunji Toya, Masaomi Iyo

{"title":"The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study.","authors":"Itaru Miura, Kentaro Takai, Shunji Toya, Masaomi Iyo","doi":"10.1097/YIC.0000000000000609","DOIUrl":"10.1097/YIC.0000000000000609","url":null,"abstract":"The aim of this analysis was to examine the impact of treatment with lurasidone on a broad range of symptoms during an acute episode of schizophrenia. In patients with an acute exacerbation of schizophrenia treated with lurasidone in a 6-week, double-blind, placebo-controlled trial, a mixed-effect model for repeated measures was used to analyze weekly change in both the five Marder Factors and the 30 individual items of the Positive and Negative Syndrome Scale (PANSS). Treatment with lurasidone was associated with significant endpoint improvement on all five Marder PANSS factors with effect sizes ranging from 0.22 to 0.44. Significant early (week 2), sustained improvement was observed on four of the five Marder Factors, with significant improvement occurring by week 4 on the Marder Negative Symptom factor. In addition to significant improvement on five out of eight Marder Positive Symptom items, the following non-Positive PANSS items were notable for being especially responsive to lurasidone treatment in terms of significant early improvement and endpoint effect sizes >0.3: anxiety, tension, preoccupation, active social avoidance, and conceptual disorganization. The results of this non-USA study confirm results from previous studies indicating that lurasidone is an effective antipsychotic medication.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"176-183"},"PeriodicalIF":3.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13015809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study. lumateperone 42 mg治疗双相情感障碍患者的长期安全性和耐受性：一项为期6个月的开放标签扩展研究的结果

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2025-11-06 DOI: 10.1097/YIC.0000000000000596

Mauricio Tohen, Suresh Durgam, Susan G Kozauer, Changzheng Chen, Robert E Davis, Sharon Mates

{"title":"Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.","authors":"Mauricio Tohen, Suresh Durgam, Susan G Kozauer, Changzheng Chen, Robert E Davis, Sharon Mates","doi":"10.1097/YIC.0000000000000596","DOIUrl":"10.1097/YIC.0000000000000596","url":null,"abstract":"This 6-month open-label extension (OLE) period of a Phase 3 placebo-controlled study (NCT02600494) examined the safety of lumateperone in patients with bipolar I or bipolar II depression. Eligible patients completing the placebo-controlled period received lumateperone 42 mg once daily up to 175 days. The primary endpoint was safety and tolerability, assessed by adverse events (AEs) and clinical laboratory evaluations analyzed by imputing missing data using a last observation carried forward approach. The secondary endpoint was efficacy measured by Montgomery-Åsberg Depression Rating Scale (MADRS) total and Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) scores. Of 127 patients in the OLE, 58.3% completed treatment, and 42.5% experienced a drug-related treatment-emergent AE (TEAE); the most common TEAEs were headache (20.5%), dry mouth (11.8%), dizziness (10.2%), and nausea (10.2%). The majority (92%) of TEAEs were of mild or moderate severity. There were no notable changes in extrapyramidal symptom scores, cardiometabolic parameters, or body morphology. MADRS total score (mean change, -8.9, nominal P < 0.0001), CGI-BP-S total score (-2.3, nominal P < 0.0001), and CGI-BP-S depression subscore (-1.3, nominal P < 0.0001) improved over time, from baseline to Day 175. Overall, 6-month lumateperone 42 mg was generally well tolerated, and depressive symptoms based on MADRS total score and CGI-BP-S improved over time.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"130-137"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the challenge of treatment adherence in major depressive disorder in different settings. 解决不同环境下重度抑郁症治疗依从性的挑战。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2026-01-28 DOI: 10.1097/YIC.0000000000000605

Gianluca Serafini

引用次数: 0

Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks. 从精神病学的角度看胰高血糖素样肽-1受体激动剂西马鲁肽：潜在益处和风险的系统评价。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2025-06-30 DOI: 10.1097/YIC.0000000000000595

Matteo Carminati, Mattia Tondello, Arianna Concina, Paolo Olgiati, Raffaella Zanardi

{"title":"Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks.","authors":"Matteo Carminati, Mattia Tondello, Arianna Concina, Paolo Olgiati, Raffaella Zanardi","doi":"10.1097/YIC.0000000000000595","DOIUrl":"10.1097/YIC.0000000000000595","url":null,"abstract":"Semaglutide (SEM), a long-acting glucagon-like peptide-1 receptor agonist, affects neural circuits regulating food intake and satiety, and it provides neuroprotective effects; however, SEM may influence psychological functioning, possibly leading to psychopathological symptoms. This review examines studies on SEM, focusing on its effects on mental health and potential neuropsychiatric side effects. A systematic search in PubMed and Google Scholar was conducted for studies up to March 2025, yielding 342 papers, of which 37 met the eligibility criteria. The selected studies included cohort studies, pharmacovigilance research, open-label studies, and randomized-controlled trials. Findings show that SEM is effective and well-tolerated in various psychiatric populations, with potential benefits in managing binge eating disorder (BED), metabolic disturbances in psychotic disorders, and alcohol use disorder; however, these drugs are also linked to depressive symptoms and suicidal ideation, alongside potential antidepressant effects, though this evidence is preliminary. SEM showed to be of great interest in the treatment of BED, acting not only on weight decrease but also on cognitive symptoms linked to the disease. Similar findings, though preliminary, have been observed for the treatment of alcohol and substance use disorder. The use of SEM in mood disorders, in particular depression, is still controversial.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"77-95"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy, suicidality, tolerability, and acceptability of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors for children and adolescents with anxiety disorders: a systematic review and meta-analysis. 选择性5 -羟色胺再摄取抑制剂和5 -羟色胺-去甲肾上腺素再摄取抑制剂治疗儿童和青少年焦虑症的疗效、自杀倾向、耐受性和可接受性：一项系统综述和荟萃分析

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2025-07-16 DOI: 10.1097/YIC.0000000000000599

Nuntaporn Karawekpanyawong, Chawanun Charnsil, Sirijit Suttajit, Manit Srisurapanont

{"title":"Efficacy, suicidality, tolerability, and acceptability of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors for children and adolescents with anxiety disorders: a systematic review and meta-analysis.","authors":"Nuntaporn Karawekpanyawong, Chawanun Charnsil, Sirijit Suttajit, Manit Srisurapanont","doi":"10.1097/YIC.0000000000000599","DOIUrl":"10.1097/YIC.0000000000000599","url":null,"abstract":"This systematic review and meta-analysis included randomized controlled trials (RCTs) to compare the efficacy, (treatment-emergent) suicidality, tolerability, and acceptability of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) against placebo in treating children and adolescents with anxiety disorders. We searched multiple electronic databases on July 15 2024. The outcomes included anxiety reduction (efficacy), suicidality rate, dropout rate because of adverse effects (tolerability), and overall dropout rate (acceptability). This study included 15 trials involving 2083 participants (median age = 11.61 years), investigating five SSRIs and two SNRIs. SSRIs/SNRIs significantly reduced anxiety symptoms [14 trials, standardized mean difference = -0.49, 95% confidence interval (CI): -0.65 to -0.33, I2 = 60%], with no significant difference between the two classes. Compared with placebo, they showed a higher risk of suicidal ideation [eight trials, risk ratio = 3.51, 95% confidence interval (CI): 1.51-8.16, I2 = 0%], greater acceptability (15 trials, risk ratio = 0.86, 95% CI: 0.75-0.99, I2 = 0%), and similar tolerability (14 trials, risk ratio = 1.30, 95% CI: 0.68-2.46, I2 = 35%). SSRIs and SNRIs effectively reduce anxiety symptoms in children and adolescents, with good tolerability and acceptability; however, they may increase the risk of suicidal ideation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"96-108"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing adherence and persistence of common selective serotonin reuptake inhibitors in veterans with major depressive disorder: a retrospective analysis of Veterans Affairs healthcare data. 比较重型抑郁症退伍军人中常见的选择性血清素再摄取抑制剂的依从性和持久性：退伍军人事务医疗保健数据的回顾性分析

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2025-08-15 DOI: 10.1097/YIC.0000000000000604

Ryan D Pittman

{"title":"Comparing adherence and persistence of common selective serotonin reuptake inhibitors in veterans with major depressive disorder: a retrospective analysis of Veterans Affairs healthcare data.","authors":"Ryan D Pittman","doi":"10.1097/YIC.0000000000000604","DOIUrl":"10.1097/YIC.0000000000000604","url":null,"abstract":"Depression has a high prevalence and increasing incidence in the USA. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are the most commonly used treatments. To be effective, SSRIs must be taken consistently. This study evaluated adherence and persistence among veterans diagnosed with major depressive disorder (MDD) who initiated SSRI monotherapy within 90 days of diagnosis. Using Veterans Affairs healthcare data from 2000 to 2023, we identified veterans with MDD who filled a prescription for one of the five most common SSRIs: citalopram, escitalopram, fluoxetine, paroxetine, or sertraline. Adherence was measured as the proportion of days covered during the first year, with greater than or equal to 80% considered adherent. Persistence was measured as time to discontinuation, defined as a 90-day gap in supply. Among 300 628 eligible patients, 29.3% were adherent and 49.6% persisted on treatment for more than 180 days. Escitalopram, fluoxetine, and sertraline had significantly higher adherence and lower discontinuation hazards compared with citalopram and paroxetine. These results suggest that escitalopram, fluoxetine, and sertraline support better long-term adherence and persistence in veterans with MDD. Enhanced understanding of these dynamics can improve patient education and support systems that address specific adherence barriers, including side effects and lack of information about treatment duration and expectations.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"109-119"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative pharmacotherapy for mood disorders: safety, cardiometabolic burden, and real-world implementation. 情绪障碍的创新药物治疗：安全性、心脏代谢负担和现实世界的实施。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2026-01-28 DOI: 10.1097/YIC.0000000000000614

Alessandro Serretti

引用次数: 0

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial. Lumateperone单药治疗双相情感障碍相关重度抑郁发作：一项随机安慰剂对照试验的疗效和安全性

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-03-01 Epub Date: 2025-07-23 DOI: 10.1097/YIC.0000000000000597

Christoph U Correll, Suresh Durgam, Susan G Kozauer, Hassan D Lakkis, Changzheng Chen, Kimberly E Vanover, Sharon Mates, Robert E Davis

{"title":"Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.","authors":"Christoph U Correll, Suresh Durgam, Susan G Kozauer, Hassan D Lakkis, Changzheng Chen, Kimberly E Vanover, Sharon Mates, Robert E Davis","doi":"10.1097/YIC.0000000000000597","DOIUrl":"10.1097/YIC.0000000000000597","url":null,"abstract":"This Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of lumateperone to treat bipolar depression. Patients (18-75 years) with bipolar I or bipolar II disorder experiencing a major depressive episode were randomized 1:1:1 to 6-week lumateperone 28 mg ( n = 183), lumateperone 42 mg ( n = 185), or placebo ( n = 186). Primary and key secondary endpoints were change from baseline to Day 43 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total score and time to first sustained response (≥50% reduction from baseline in MADRS Total score), respectively. Safety assessments included adverse events, extrapyramidal symptoms (EPS), laboratory evaluations, and vital signs. Neither dose of lumateperone achieved significant improvement vs. placebo ( P > 0.05) in the primary endpoint (MADRS Total score, least squares mean difference vs. placebo: 28 mg, 0.9; 42 mg, -1.0) or in the key secondary endpoint (MADRS Total time to first sustained response hazard ratio vs. placebo: 28 mg, 1.00; 42 mg, 0.93), likely due to a high placebo response. Both lumateperone doses were well tolerated, with low EPS risk and minimal changes in weight, prolactin, and cardiometabolic or endocrine parameters. While study efficacy objectives were not met, both doses of lumateperone were generally safe and well tolerated in patients with bipolar depression.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"120-129"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. 利培酮作为双相情感障碍患者强迫症症状的辅助治疗：一项随机、双盲、安慰剂对照的临床试验

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-05-21 DOI: 10.1097/YIC.0000000000000592

Ali Sahraian, Mahsa Ghavipisheh, Leila Razeghian Jahromi, Iman Ahrari, Arash Mowla

{"title":"Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial.","authors":"Ali Sahraian, Mahsa Ghavipisheh, Leila Razeghian Jahromi, Iman Ahrari, Arash Mowla","doi":"10.1097/YIC.0000000000000592","DOIUrl":"10.1097/YIC.0000000000000592","url":null,"abstract":"Treatment of obsessive-compulsive disorder (OCD) symptoms in patients with bipolar disorder (BD) is challenging. In this research, the therapeutic effects of risperidone on OCD symptoms in patients with BD are investigated. Forty-two patients with concurrent BD and OCD symptoms were randomly assigned to receive risperidone or a placebo in a blinded randomized placebo-controlled trial. The patients of both groups were in the euthymic phase of BD. OCD symptoms were measured by the Yale-Brown Obsessive Compulsive Behavior Scale (YBOCS) before the study initiation and at the 4 th ,8 th , and 12 th weeks in each group. All the patients completed the trial with no dropouts. At the initial evaluation, the risperidone and placebo groups did not differ significantly regarding their YBOCS scores. After 12 weeks of treatment, the OCD symptoms were significantly lower in the risperidone group compared to the placebo group [YBOCS: 5(3) vs. 11(6.5), P -value < 0.001]. The number of patients with more than 35% reduction in YBOCS was significantly higher in the risperidone group compared to the placebo group [20/21 (95.23%) vs. 10/21 (47.61%), P -value = 0.001]. Risperidone could effectively reduce OCD symptoms in BD patients. The treatment was safe and well tolerated.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"52-56"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and correlates of prescription drug abuse and misuse among adult prisoners: a systematic review. 成人囚犯中处方药滥用和误用的流行程度及其相关因素：系统回顾。

IF 2.5 3区医学

International Clinical Psychopharmacology Pub Date : 2026-01-01 Epub Date: 2025-03-07 DOI: 10.1097/YIC.0000000000000586

Enrico Capuzzi, Massimiliano Buoli, Francesco Butturini, Nadia Bolognini, Massimo Clerici

{"title":"Prevalence and correlates of prescription drug abuse and misuse among adult prisoners: a systematic review.","authors":"Enrico Capuzzi, Massimiliano Buoli, Francesco Butturini, Nadia Bolognini, Massimo Clerici","doi":"10.1097/YIC.0000000000000586","DOIUrl":"10.1097/YIC.0000000000000586","url":null,"abstract":"There is a growing concern about the inappropriate use of prescription drugs in correctional facilities because of the impact on mental and physical health, drug interactions, risk of overdoses, and drug-related deaths. This study systematically examines the prevalence of abuse and misuse of prescription medications in correctional facilities and factors associated among adult individuals who are incarcerated. A systematic search was performed including articles in English, up to 31 August 2024. Fourteen relevant studies were included. The most reported prescription drugs in custodial settings were opioid substitution treatments, opioid and non-opioid analgesics, and gabapentinoids. Inappropriate use of benzodiazepines resulted also to be relevant. Inconsistency in the definition of abuse and misuse as well as the important heterogeneity in population characteristics and study designs prevent us to draw definitive conclusions as regards the prevalence of abuse and misuse of prescription treatments in custodial settings. Few and inconsistent correlations emerged from available literature. Monitoring inappropriate use of prescription medicines in correctional facilities is warranted. In particular, institutions, policy-makers, and healthcare professionals should jointly provide appropriate intervention strategies. Future research should be taken into account the important limitations of the existing literature.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"6-24"},"PeriodicalIF":2.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0